A Phase II, Multicenter, Single-Arm Study OF Atezolizumab In Patients With PD-L1-Positive Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
A Phase II, Multicenter, Single-Arm Study OF Atezolizumab In Patients With PD-L1-Positive Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
This multicenter, single-arm study will evaluate the efficacy and safety of Atezolizumab in participants with PD-L1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). Participants will receive Atezolizumab 1200 milligrams (mg) intravenously every 3 weeks as long as participants are experiencing clinical benefit as assessed by the investigator, that is , in the absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression.
Inclusion Criteria:
Exclusion Criteria:
Hormone-replacement therapy or oral contraceptives tyrosine-kinase inhibitors (TKIs) approved for treatment of NSCLC discontinued >7 days prior to Cycle 1, Day 1
Aurora, Colorado 80045, United States
Washington D.C., District of Columbia 20007, United States
Chicago, Illinois 60637, United States
Woolloongabba, Queensland 4102, Australia
Sarajevo, 71000, Bosnia and Herzegovina
Toronto, Ontario M5G 2M9, Canada
Nantes, 44805, France
Nuremberg, 90419, Germany
Villingen-Schwenningen, 78052, Germany
Meldola, Emilia-Romagna 47014, Italy
Orbassano, Piedmont 10043, Italy
Fukuoka, 810-8563, Japan
Singapore, 119228, Singapore
Zurich, 8091, Switzerland
Malatya, 44280, Turkey (Türkiye)